B7-H3-Specific Chimeric Antigen Receptor Autologous T-Cell Therapy for Pediatric Patients With Solid Tumors (3CAR)
Phase 1
32
about 4.7 years
≤21
1 site in TN
About this study
Researchers are testing a new treatment called B7-H3 CAR T cells to see if it can help children with certain types of solid tumors. The trial will evaluate the safety and how well this treatment works in kids aged 18 or younger who have relapsed or refractory B7-H3+ solid tumors. It aims to determine the maximum safe dose of these CAR T cells.
Based on ClinicalTrials.gov records.
What participants do
- 1.Take B7-H3 CAR T cells
- 2.Take Cyclophosphamide
- 3.Take Fludarabine
- +1 more
Participation effort
Estimated from trial records. Details can vary by site.
Logistics difficulty varies by site location and availability.
Trial highlights
Treatment details
Auto-extracted from trial records to preview treatments and outcomes.
cell therapy (Engineered T-cells that target specific cancer antigens), cyclophosphamide (Alkylating chemotherapy; crosslinks DNA strands), fludarabine, mesna
infusion, oral (Oral Tablet)
Secondary: Clinical Response
Oncology